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Background Rewiring cellular metabolism is important for activation of immune cells during host 
defense against Mycobacterium tuberculosis. Glutamine has been implicated as an 
immunomodulatory nutrient, but its role in response to M. tuberculosis is unknown.  
Methods We assessed expression of glutamine pathway genes in M. tuberculosis infected 
macrophages and blood transcriptomics from individuals with latent or active tuberculosis. 
Subsequently, we studied the effect of blocking glutaminolysis on M. tuberculosis-induced cytokines. 
Finally, we examined whether polymorphisms in genes involved in the glutamine pathway influence 
M. tuberculosis-induced cytokines in a cohort of 500 individuals. 
Results Glutamine pathway genes were differentially expressed in infected macrophages and 
patients with active tuberculosis. Human peripheral blood mononuclear cells stimulated with M. 
tuberculosis displayed decreased cytokine responses (IL-1β, IFN-γ, and IL-17) when medium was 
devoid of glutamine. Specific inhibitors of the glutamine pathway led to decreased cytokine 
responses, especially T-cell cytokines (IFN-γ, IL-17, and IL-22). Finally, genetic polymorphisms in 
glutamine metabolism genes (including GLS2, SLC1A5, and SLC7A5) influenced ex-vivo cytokine 
responses to M. tuberculosis, especially for T-cell cytokines.  
Conclusions Cellular glutamine metabolism is implicated in effective host responses against M. 
tuberculosis. Targeting immunometabolism may represent new strategies for TB prevention and/or 
treatment.  
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Changes in cellular metabolism play a vital role in the initiation and regulation of the immune 
response. Once infected, immune cells undergo rewiring of cellular metabolism to adapt to the 
infection and generate sufficient energy to carry out host defense functions. Metabolic 
reprogramming is also important for host responses against Mycobacterium tuberculosis (M. 
tuberculosis), the causative agent of tuberculosis (TB). M. tuberculosis induces a switch in cellular 
metabolism in peripheral blood mononuclear cells (PBMCs) towards aerobic glycolysis. This 
metabolic switch is mediated through the AKT-mTOR pathway, and inhibition of glycolysis results in 
reduced cytokine production and mycobacterial killing (1, 2). We have recently identified other 
metabolic pathways, including glutathione and pyrimidine metabolism, to be differentially expressed 
at tissue level in tuberculosis patients, and to alter Th1 and Th17 production in response to M. 
tuberculosis (3). However, the role of other metabolic pathways on the immune response against M. 
tuberculosis remains largely unknown.  
Glucose can be used to generate ATP either through glycolysis, which involves the conversion of 
glucose to pyruvate and thereafter through fermentation to lactate in the cytoplasm, or by oxidation 
of pyruvate in the tricarboxylic acid (TCA) cycle, which generates nicotinamide adenine dinucleotide 
(NADH) and flavin adenine dinucleotide (FADH2) to fuel oxidative phosphorylation (OXPHOS) (4). 
Glutamine, a non-essential amino acid, can be used as an additional carbon source to fuel the TCA 
cycle by a process called glutaminolysis. To accomplish this, glutamine is converted to glutamate by 
the enzyme glutaminase, and the enzyme glutamate dehydrogenase (GDH) mediates the conversion 
from glutamate to α-ketoglutarate (α-KG), which is a substrate for the TCA cycle. The importance of 
glutamine metabolism during activation of host defense has been described in other infections. For 
instance, during cytomegalovirus infection, glutamine consumption increases, and infected cells 
become dependent upon glutamine for ATP production (5). In addition, glutaminolysis is essential for 




















The aim of this study was to examine the relevance of glutamine metabolism in host responses 
against M. tuberculosis. To this purpose, we assessed whether genes involved in glutaminolysis are 
modulated during M. tuberculosis infection; we studied the effect of blocking glutaminolysis on M. 
tuberculosis-induced cytokines; and we examined if variation in glutamine pathway genes acted as 






















Peripheral blood mononuclear cell (PBMC) isolation and stimulation 
Informed consent from healthy volunteers was obtained for use of their blood for scientific purposes, 
as approved by the Ethics Committee of Radboud University Medical Centre, Nijmegen, the 
Netherlands. Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats obtained 
from healthy volunteers (Sanquin Bloodbank, Nijmegen, the Netherlands). Isolation was performed 
using Ficoll-Paque, involving separation by a density gradient followed by three wash steps in cold 
PBS and resuspension in RPMI 1640 (Life Technologies, Paisley, UK) supplemented with 10 μg/mL 
gentamicin, 2 mM GlutaMAX (except for the glutamine depletion experiment), and 5.5 mmol/L 
glucose. After isolation, PBMCs (5 x 105 cells/well) were seeded in 96-well round-bottom plates and 
stimulated with M. tuberculosis H37Rv lysate (1 µg/mL), Candida albicans (1 × 106 copies/mL), 
Staphylococcus aureus (1 × 106 copies/mL), PHA (10 µg/mL) or culture medium. The cultures were 
incubated for 24 h or 7 days at 37°C in 5% CO2, and supplemented with 10% human pooled serum in 
case of a 7-day stimulation, after which supernatants were collected and stored at −20°C. In some 
experiments, cells were pre-incubated (before stimulation) for 1 h with 600 μM gamma-L-Glutamyl-
p-Nitroanilide (GPNA), 10 μM 6-Diazo-5-oxo-L-norleucine (DON), 30 μM C968, 50 μM BPTES (Sigma), 
or 5 mM aminooxyacetate (AOA).  
Cytokine and lactate measurements 
Enzyme-linked immunosorbent assays (ELISAs) were performed on supernatants from the PBMC 
stimulations following the manufacturer’s protocols for measuring cytokines in supernatants. The 
concentrations of interleukin-1β (IL-1β), tumor necrosis factor α (TNF-α) (R&D Systems, Minneapolis, 
Minnesota, USA), IL-10 and IL-6 (Sanquin, Amsterdam, the Netherlands) were measured after 1 day 




















(R&D Systems, Minneapolis, Minnesota, USA) were measured after 7 days. Lactate concentrations 
were measured after 1 day of incubation using Fluorometric Quantification Assay Kits (Biovision). 
Metabolite measurements 
After cell culture, cells were lysed in 0.5% Triton-X in PBS. Concentrations of fumarate, glutamate, 
pyruvate, KG, and malate were determined by commercial kits (Sigma), according to the 
instructions of the manufacturer. 
Cell death assay 
To measure the effect of the tested inhibitors on cell death, annexin V-FITC conjugate (Av, BioVision, 
Milpitas, California, USA) and propium iodide (PI) were added after stimulation. Annexin V stains 
phosphatidylserine translocating from the inner to the outer leaflet of the membrane, marking early 
apoptosis. PI stains nuclei from cells that are permeable, reflecting cell death, either from advanced 
apoptosis or necrosis. Flow cytometric analysis using Cytomics FC500 was performed to distinguish 
Av- /PI- (alive), Av+ /PI- (early apoptotic) and Av+ /PI+ (advanced apoptotic / necrotic) populations.  
In-vitro gene expression dataset 
CD14+ monocytes were isolated from PBMCs by magnetic cell sorting with anti-CD14-coated MACS 
microbeads (Miltenyi Biotec) and seeded in tissue culture-treated flasks (Corning). After 6 days of 
differentiation in the presence of 50 ng/mL M-CSF, macrophages were harvested using trypsin and 
transferred to tissue culture-treated 24-well plates (Corning) with 300,000 macrophages per well. 
Macrophages were incubated O/N at 37°C in 5% CO2 and subsequently infected with the H37Rv 
strain of M. tuberculosis. Bacterial density was determined by measuring optical density at 600 nm 
(OD600) and the bacterial suspension was diluted to a concentration of 30 x 10
6 bacteria/mL to infect 
the macrophages at a multiplicity of infection (MOI) of 10. 100 μL of the bacterial suspension was 




















incubated at 37°C in 5% CO2. After 60 minutes the plates were washed with culture medium 
containing 30 μg/mL gentamicin to kill extracellular bacteria and subsequently incubated O/N at 37°C 
in 5% CO2 in medium containing 5 μg/mL gentamicin. Cells were lysed by direct addition of TRIzol to 
the wells, followed by RNA extraction. RNAseq libraries were prepared from 1 μg RNA using the 
TruSeq RNA sample preparation kit v2 (Illumina) according to the manufacturer’s instructions, and 
these libraries were subsequently sequenced on a HiSeq 2000 sequencer (Illumina) using single-end 
sequencing of 50 bp, upon pooling of 10 samples per lane. 
In-vivo gene expression dataset 
We downloaded previously published whole blood microarray data from patients with pulmonary TB 
(culture positive), latent TB and healthy controls (TST and IGRA negative) (7). Each microarray was 
scaled to the median average intensity for all samples (per-chip normalization). These data were 
obtained from Gene Expression Omnibus (GEO) under accession number GSE19491.  
Cytokine quantitative trait loci (cQTL) analyses 
Single nucleotide polymorphisms (SNPs) in sixteen genes from the glutamine pathway were 
identified. SNPs were then mapped (p<0.05 cut-off) for cytokine quantitative trait loci (QTLs) in the 
500FG cohort. This cohort consists of 500 healthy individuals of Dutch European ancestry from the 
Human Functional Genomics Project (www.humanfunctionalgenomics.org), from which peripheral 
blood mononuclear cells (PBMC) or macrophages have been stimulated by heat-killed M. tuberculosis 
and the secretion of IFN-, IL-17, IL-22 (7 days post-stimulation) and IL-1, IL-6 and TNF- (24h post-
stimulation) measured, as previously described (8). To identify cQTLs, raw cytokine levels were first 
log transformed then mapped to genotype data using a linear regression model with age and gender 
as covariates. P values were obtained using linear regression analysis of cytokine on genotype data, 























The non-parametric Wilcoxon matched-pairs signed rank test was used to compare cytokine and 
metabolite data from the in-vitro experiments between groups. P-values of 0.05 or less were 
considered statistically significant. These statistical analyses were performed using GraphPad Prism 
5.03. To analyze the gene expression datasets, principal component analyses (PCA) were performed 
on centered, scaled data using ‘prcomp’. The heatmap was generated using 'heatmap', and samples 
were ordered using hierarchical clustering. All analyses performed on gene expression data were 





















Transcriptional changes in genes involved in glutamine metabolism in vivo and in M. tuberculosis-
infected macrophages  
We examined whether M. tuberculosis infection leads to an altered expression of genes of the 
glutamate pathway, using in-vitro infected macrophages and available blood transcriptome data 
from patients and controls. Based on expression of genes from the glutamine pathway, M. 
tuberculosis-infected macrophages could be clearly separated from uninfected macrophages using 
principal component analysis (Figure 1a). To further understand the class separation between 
infected versus uninfected macrophages, samples were clustered using unsupervised hierarchical 
clustering method using the gene expression of these glutamine-pathway genes. Two major clusters 
were found, one containing the M. tuberculosis-infected macrophages, and one with the uninfected 
macrophages (Figure 1b). Overall, M. tuberculosis infection led to higher expression of genes 
involved in transport and glutamine utilization. In addition, M. tuberculosis infection decreased 
expression of several genes involved in the TCA cycle, whereas ME2, which converts malate into 
pyruvate, and GLUD2, which converts glutamine to α-ketoglutarate, were specifically upregulated. 
Pulmonary TB patients and uninfected control subjects were clearly separated based on their whole 
blood expression of these glutamine-pathway genes, while individuals with latent tuberculosis 
infection (LTBI) were spread throughout the plot (Figure 1c).  
M. tuberculosis-induced cytokines are decreased after glutamine depletion 
To study the effect of M. tuberculosis on glutamine metabolism, we assessed whether M. 
tuberculosis stimulation increased the production of glutamine-derived metabolites in vitro. 
Peripheral blood mononuclear cells (PBMCs) stimulated with M. tuberculosis showed a significant 
increase in intracellular glutamate and malate (Wilcoxon signed-ranked test, p = 0.019 and 0.022, 




















Subsequently, we examined the effect of glutamine deprivation on the cytokine production in 
response to M. tuberculosis. Glutamine depletion resulted in a significant decrease in IL-1β, IFN-γ, 
and IL-17 produced by PBMCs (Wilcoxon signed-ranked test, p = 0.004, 0.020, and 0.037, 
respectively) (Figure 2b). To study whether this decrease in cytokines upon glutamine deprivation 
was linked to lactate production, lactate levels were measured in supernatants from cultured 
monocytes and PBMCs. No differences in lactate were observed (Figure 2c), suggesting that 
glutamate is not a fuel for lactate production upon stimulation with M. tuberculosis.  
Inhibition of glutamine transport and metabolizing enzymes decrease cytokine production 
To determine which steps of glutamine utilization influence cytokine production by M. tuberculosis-
stimulated PBMCs, pharmacologic inhibitors were added during culture. A schematic diagram 
indicating the site of action of the different inhibitors is depicted in Figure 3. Firstly, addition of 
GPNA, a competitive inhibitor of the glutamine uptake via SLC1A5 glutamine transporter, led to a 
decrease in the production of TNF-α and IL-17. Next, the effects of inhibition of glutaminase, an 
enzyme responsible for the conversion of glutamine into glutamate, the first step of glutaminolysis, 
was examined using three different compounds: DON, BPTES and C968. Addition of DON, a broad 
spectrum glutaminase inhibitor, significantly lowered the production of IL-17, IFN-γ, and IL-22 during 
stimulation of PBMCs, but did not affect any of the monocyte-derived cytokines. The effects of DON 
are not specific for M. tuberculosis-induced cytokines, as C. albicans-induced IL-17 and IL-22 are also 
affected by glutaminase inhibition (Supplementary Figure 1). BPTES and C968 are both specific 
inhibitors of mitochondrial glutaminase (GLS1). BPTES inhibited the production of IL-10, IL-17 and IL-
22, while C986 suppressed the release of IL-1β, IL-10, IL-17, IFN-γ, and IL-22. Finally, we examined the 
conversion of glutamate into α-ketoglutarate, using AOA, which inhibits aminotransferase. Almost all 
cytokines tested were suppressed by AOA, except for IL-10. The effects of these inhibitors on the 




















The impact of genetic variants on glutamine-dependent cytokine responses 
Lastly, we examined whether genetic variation in genes involved in the glutamine pathway affects 
host response to M. tuberculosis. To do so, we tested if common genetic variants (minor allele 
frequency ≥ 5%) in glutamine-related genes are associated with differences in cytokine secretion in 
response to M. tuberculosis stimulation, using a cohort of 500 healthy individuals from the Human 
Functional Genomics Project (www.humanfunctionalgenomics.org). We identified 13 cytokine 
quantitative trait loci (cQTLs) in 7 genes related to glutamine metabolism (Table 1). The strongest 
cQTLs were identified in genes encoding for the high affinity glutamine receptor, SLC1A5, and two 
enzymes involved in the conversion of glutamine to glutamate, GLS and GLUD. Finally, we 
investigated the known effects of the identified QTLs on gene expression. This was done using the 
publically available cohort of Westra et al. who performed an expression QTLs (eQTLs) meta-analysis 
in non-transformed peripheral blood samples (9). Four of our identified cytokine QTLs were also 
known eQTLs (Table 1). This means that these genetic variants regulate both gene expression and 





















A growing body of evidence supports the importance of cellular metabolism during immune 
activation and host defense against tuberculosis. For the first time, we examined the role of 
glutamine metabolism in M. tuberculosis infection. Transcriptional changes in glutamine-related 
genes were evident in vitro in M. tuberculosis infected macrophages and cells from pulmonary 
tuberculosis patients compared to healthy subjects. Glutamine depletion or glutamine pathway 
inhibitors predominantly reduced T-helper cell cytokine production. These findings were 
substantiated by the identification of SNPs in genes of the glutamine pathway that affected cytokine 
production in response to M. tuberculosis stimulation of human PBMCs. Together, these data 
underline the importance of glutamine metabolism in tuberculosis.  
 
Interestingly, most glutamine metabolism inhibitors appeared to affect stronger the T cell-derived 
cytokine production (IFN-γ, IL-17, and IL-22) compared to monocyte-derived cytokines (TNF-α, IL-6, 
IL-1β, and IL-10), suggesting a more prominent role for glutamine metabolism in the differentiation 
of T helper cells. This is supported by data from Nakaya et al, who showed that stimulation of naïve 
CD4+ T cells triggered glutamine uptake, and that glutamine was required for the differentiation of 
naïve T cells to Th1 and Th17 inflammatory T cells (10). The critical role for T cell immunity in the 
control of M. tuberculosis is evident, as defects in Th1 cytokine production, particularly IFN-γ, are risk 
factors for infection and disease progression (11). A balance between Th1 and Th17 responses is 
essential to control bacterial growth and limit immunopathology, as a shift of the response towards 





















Genes involved in the glutamine pathway were differentially expressed after M. tuberculosis 
stimulation in vitro. We also observed genetic polymorphisms in glutamine pathway genes, including 
GLS2, SLC1A5 and SLC7A5, that controlled M. tuberculosis-induced cytokine production, which 
further strengthens the role of glutamine metabolism in the host defense against M. tuberculosis.  
This is not the first study that observed immunomodulatory effects of glutamine. In an experimental 
cerebral malaria study, inhibition of glutamine metabolism improved survival of mice by inhibiting 
CD8+ T cell effector functions (13). In addition, glutaminolysis is essential for the induction of innate 
immune memory, termed trained immunity (6). In a murine study, a sustained trained immunity 
response was induced by β-glucan through modulation of hematopoietic stem en progenitor cells 
(HSPCs), which was associated with adaptations in glucose metabolism and cholesterol biosynthesis 
(Mitroulis cell 2018). Interestingly, intravenous BCG vaccination also led to changes in HSPCs, and 
these epigenetically modified macrophages provide better protection against M. tuberculosis 
infection (Kaufmann 2018 cell). Therefore, targeting the glutamine pathway might be a promising 
approach to modulate the immune response against M. tuberculosis through modulation of trained 
immunity. 
 
Our study has some limitations. The cytokines studied in our in-vitro assays and the cQTL analysis 
represent only one component of the host immune response against M. tuberculosis infection. The 
role of glutamine metabolism on other aspects of the immune response, for example mycobacterial 
killing or phagocytosis, have not been explored in this study. Also, the relevance of glutamine 
metabolism during in-vivo infection is yet to be fully explored. Future studies should investigate the 
role of glutamine metabolism in live infection models, and study its role in susceptibility to 
tuberculosis in infected patients. In addition, tracer infusion studies could help unravel the in-vivo 





















In conclusion, our study has identified glutamine metabolism as a fundamental metabolic process 
needed to mount an effective host response against M. tuberculosis. Earlier, we have identified other 
metabolic pathways, including glutathione and pyrimidine metabolism, to be relevant for host 
responses in tuberculosis (3). These studies and others underline the relevance of cellular 
metabolism for the response of immune cells to M. tuberculosis, and its potential role in developing 
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Figure 1. M. tuberculosis induces transcriptional changes in genes involved in glutamine 
metabolism  
(A) Principal component analysis of the glutamine gene signatures of macrophages stimulated with 
either live or dead M. tuberculosis, with proportion of variance per principal component indicated 
between brackets.  
(B) Heatmap of gene expression pattern of glutamine genes in in vitro‐stimulated macrophages. 
Samples (unstimulated or infected) were ordered by hierarchical clustering.  
(C) Principal component analysis of the glutamine whole blood gene signatures of microarray data 
from a publically available cohort from South Africa, including pulmonary TB patients (PTB), latently 
infected individuals (LTBI), and healthy controls.  
 
Figure 2. M. tuberculosis-induced cytokines are decreased after glutamine depletion 
(A) PBMCs were stimulated with M. tuberculosis for 24h and intracellular glutamine metabolites 
were measured afterwards. 
(B) PBMCs were stimulated with M. tuberculosis in the presence (black bars) or absence (grey bars) 
of glutamine and extracellular cytokines were measured after 24h of stimulation (TNF-α, IL-1β, IL-6 
and IL-10) or 7 days (IFN-γ, IL-17 and IL-22). 
(C) PBMCs were stimulated with M. tuberculosis in the presence (black bars) or absence (grey bars) of 
glutamine and extracellular lactate was measured after 24 h. 
 
Figure 3. Schematic diagram of metabolic pathways and site of action of inhibitors 
The schematic is adapted from Hensley et al. (15). Metabolites are depicted in black, enzymes or 





















Figure 4. Inhibition of glutamine transport and metabolizing enzymes decrease M. tuberculosis-
induced cytokine production  
PBMCs were stimulated with M. tuberculosis in the absence (grey bars) of presence (black bars) of 
specific inhibitors (GPNA, DON, BPTES, C968 or AOA) and extracellular cytokines were measured 




















Table 1: cytokine QTL results  
  
T-cell cytokines Monokines  
       
Gene SNP IFN-y IL-17 IL-22 IL-1β IL-6 eQTL Gene function 
GLS2 rs2657879      0.002     2,22E-05 Converts Gln to Glu 
GCLM rs3112831    0.034       - Converts Glu & Cys to Glutathione 
GLUD1 rs760113  0.038         - 




  - 
  rs77879311    0.005       - 
GPT rs1063739          0.020 3,07E-51 Converts Ala & 2-oxoglutarate to 










High affinity L-glutamine transporter,  
takes up glutamine 
SLC3A2 rs12808829  0.036         - Antiporter. Exchanges intracellular 
Gln for extracellular Leu 
 
  rs6856   0.046   0.021   - 
  rs4963245          0.036 - 
SLC7A5 rs34779002      0.024     - Antiporter. Exchanges intracellular 
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